Mass spectrometry of selective androgen receptor modulators

Journal of Mass Spectrometry

Volumn 43, Issue 7, 2008, Pages 865-876

  Thevis, Mario ^a   Schänzer, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Anabolics; Doping; Mass spectrometry; Orbitrap; SARMs; Sport

Indexed keywords

CHEMOTHERAPY; DISSOCIATION; DRUG DELIVERY; DRUG DOSAGE; HEALTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION; MASS SPECTROMETERS; MASS SPECTROMETRY; MUSCLE; SIGNAL DETECTION; SPECTROMETRY; WEIGHT CONTROL;

AGE-RELATED; ANDROGEN RECEPTOR (AR); CHEMICAL STRUCTURES; CLINICAL TRIALS; COLLISION INDUCED DISSOCIATION (CID); DETECTION METHODS; DISSOCIATION PATHWAYS; DOPING CONTROL; ELECTRON IONIZATION (EI); ELECTROSPRAY IONIZATION (ESI); FRAGMENTATION PATTERNS; HYDANTOIN; LOW-MOLECULAR-WEIGHT (LMW); METABOLIC PRODUCTS; MUSCLE STRENGTH; MUSCLE WASTING; OSTEOPOROSIS (OP); STRUCTURAL HETEROGENEITIES; SYNTHETIC ANALOGS; TARGET ANALYTES; TETRAHYDROQUINOLINE (THQ); WORLD ANTI DOPING AGENCY (WADA);

ELECTROSPRAY IONIZATION;

ANABOLIC AGENT; BICALUTAMIDE; BICYCLO COMPOUND; BMS 564929; FLUTAMIDE; HYDANTOIN DERIVATIVE; LG 121071; LGD 2226; NILUTAMIDE; OSTARINE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROPIONAMIDE DERIVATIVE; QUINOLINE DERIVATIVE; S 40503; SELECTIVE ANDROGEN RECEPTOR MODULATOR;

ANALYTIC METHOD; COLLISIONALLY ACTIVATED DISSOCIATION; DOPING; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; REVIEW;

ANABOLIC AGENTS; ANDROGEN ANTAGONISTS; DOPING IN SPORTS; HUMANS; MALE; RECEPTORS, ANDROGEN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPORTS; SUBSTANCE ABUSE DETECTION;

EID: 47749101721     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1438     Document Type: Review

References (65)

1. de Kruif P. The Male Hormone. Harcourt, Brace and Company: New York, 1945.
2. Maisel AQ. The Hormone Quest. Random House: New York, 1965.
3. Butenandt A, Hanisch G. Über testosteron. Umwandlung des dehydroandrosterons in androstendiol und testosteron, ein weg zur darstellung des tesotosterons aus cholesterin. Hoppe-Seyler's Zeitschrift fur Physiologische Chemie 1935; 237: 89.
4. Ruzicka L, Wettstein A. Sexualhormone VII. Über die künstliche Herstellung des testikelhormons testosteron (Androsten-3-on-17-ol). Helvetica Chimica Acta 1935; 18: 1264.
5. Kochakian CD. Metabolic effects of anabolic-androgenic steroids in experimental animals. In Anabolic-Androgenic Steroids, vol. 43, Kochakian CD (ed). Springer: Berlin, 1976; 5.
6. Ruzicka L, Goldberg MW, Rosenberg HR. Sexualhormone X. Herstellung des 17-Methyltestosteron und anderer androsten-und androstanderivate. Zusammenhänge zwischen chemischer konstitution und männlicher hormonwirkung. Helvetica Chimica Acta 1935; 18: 1487.
7. Rommerts FFG. Testosterone: an overview of biosynthesis, transport, metabolism and non-genomic actions. In Testosterone - Action, Deficiency, Substitution, Nieschlag E, Behre HM (eds). Cambridge University Press: Cambridge, 2004; 1.
8. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861.
9. Chen J, Kim J, Dalton JT. Discovery and therapeutic promise of selective androgen receptor modulators. Molecular Interventions 2005; 5: 173.
10. Bagatell CJ, Bremner WJ. Androgens in men-uses and abuses. New England Journal of Medicine 1996; 334: 707.
11. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3459.
12. Cadilla R, Turnbull P, Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Current Topics in Medicinal Chemistry 2006; 6: 245.
13. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD. Discovery of nonsteroidal androgens. Biochemical and Biophysical Research Communications 1998; 244: 1.
14. Mohler ML, Nair VA, Hwang DJ, Rakov IM, Patil R, Miller DD. Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates. Expert Opinion on Therapeutic Patents 2005; 15: 1565.
15. GTx, Incorporated. Ostarine achieved the primary endpoint of increasing lean body mass and a secondary endpoint of improving functional performance, 2006; http://www.salesandmarketingnetwork.com/news_release.php?ID=2015328 (08-12-2006).
16. World Anti-Doping Agency. The 2008 prohibited list, 2008; http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf (28-11-2007).
17. Thevis M, Schänzer W. Emerging drugs - potential for misuse in sport and doping control detection strategies. Mini-Reviews in Medicinal Chemistry 2007; 7: 533.
18. Thevis M, Schänzer W. Mass spectrometry in doping control analysis. Current Organic Chemistry 2005; 9: 825.
19. Thevis M, Schänzer W. Current role of LC-MS(/MS) in doping control. Analytical and Bioanalytical Chemistry 2007; 388: 1351.
20. Thevis M, Schänzer W. Mass spectrometry in sports drug testing: structure characterization and analytical assays. Mass Spectrometry Reviews 2007; 26: 79.
21. Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical Research 2006; 23: 1641.
22. Wu Z, Gao W, Phelps MA, Wu D, Miller DD, Dalton JT. Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry. Analytical Chemistry 2004; 76: 839.
23. Gao W, Wu Z, Bohl CE, Yang J, Miller DD, Dalton JT. Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations. Drug Metabolism and Disposition 2006; 34: 243.
24. Thevis M, Kamber M, Schänzer W. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Communications in Mass Spectrometry 2006; 20: 870.
25. Wu D, Wu Z, Yang J, Nair VA, Miller DD, Dalton JT. Pharmacokinetics and metabolism of a selective androgen receptor modulator (SARM) in rats-implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metabolism and Disposition 2006; 34: 483.
26. Kuuranne T, Leinonen A, Schänzer W, Kamber M, Kostiainen R, Thevis M. Aryl-propionamide-derived selective androgen receptor modulators: LC-MS/MS characterization of the in vitro synthesized metabolites for doping control purposes. Drug Metabolism and Disposition 2008; 36: 571.
27. Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG Jr. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2006; 48: 4.
28. Sun C, Robl JA, Wang TC, Huang Y, Kuhns JE, Lupisella JA, Beehler BC, Golla R, Sleph PG, Seethala R, Fura A, Krystek SR, An Y, Malley MF, Sack JS, Salvati ME, Grover GJ, Ostrowski J, Hamann LG Jr. Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-arylhydroxybicyclohydantoin scaffold. Journal of Medicinal Chemistry 2006; 49: 7596.
29. Hamann LG, Manfredi MC, Sun C, Krystek SR, Huang Y, Bi Y, Augeri DJ, Wang T, Zou Y, Betebenner DA, Fura A, Seethala R, Golla R, Kuhns JE, Lupisella JA, Darienzo CJ, Custer LL, Price JL, Johnson JM, Biller SA, Zahler R, Ostrowski J Jr. Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters 2007; 17: 1860.
30. Shen JX, Brodbelt J. Reactions of hydantoin and succinimide anticonvulsants with dimethyl ether ions in a quadrupole ion trap mass spectrometer. Journal of Mass Spectrometry 1996; 31: 1389.
31. Wang F, Ma S, Zhang D, Cooks RG. Proton affinity and gasphase basicity of urea. Journal of Physical Chemistry 1998; 102: 2988.
32. Thevis M, Kohler M, Schlörer N, Kamber M, Kuhn A, Linscheid MW, Schänzer W. Mass spectrometry of hydantoin-derived selective androgen receptor modulators. Journal of Mass Spectrometry 2008; 43: 639.
33. Wysocki VH, Tsaprailis G, Smith LL, Breci LA. Mobile and localized protons: a framework for understanding peptide dissociation. Journal of Mass Spectrometry 2000; 35: 1399.
34. Paizs B, Suhai S. Fragmentation pathways of protonated peptides. Mass Spectrometry Reviews 2005; 24: 508.
35. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)- pyrrolidino[3,2-g] quinolinone. Bioorganic and Medicinal Chemistry Letters 1998; 8: 745.
36. Edwards JP, Higuchi RI, Winn DT, Pooley CL, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorganic and Medicinal Chemistry Letters 1999; 9: 1003.
37. Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). Journal of Medicinal Chemistry 1999; 42: 210.
38. van Oeveren A, Motamedi M, Mani NS, Marschke KB, Lopez FJ, Schrader WT, Negro-Vilar A, Zhi L. Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino-4- trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. Journal of Medicinal Chemistry 2006; 49: 6143.
39. van Oeveren A, Motamedi M, Martinborough E, Zhao S, Shen Y, West S, Chang W, Kallel A, Marschke KB, Lopez FJ, Negro-Vilar A, Zhi L. Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorganic and Medicinal Chemistry Letters 2007; 17: 1527.
40. van Oeveren A, Pio BA, Tegley CM, Higuchi RI, Wu M, Jones TK, Marschke KB, Negro-Vilar A, Zhi L. Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones. Bioorganic and Medicinal Chemistry Letters 2007; 17: 1523.
41. Wang F, Liu XQ, Li H, Liang KN, Miner JN, Hong M, Kallel EA, van Oeveren A, Zhi L, Jiang T. Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226. Acta Crystallographica Section F Structural and Biological Crystallography Communication 2006; 62: 1067.
42. Rosen J, Negro-Vilar A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. Journal of Musculoskeletal and Neuronal Interactions 2002; 2: 222.
43. Kami M, Mandelbaum A. The "Even-Electron-Rule". Organic Mass Spectrometry 1980; 15: 53.
44. Levsen K, Schiebel HM, Terlouw JK, Jobst KJ, Elend M, Preiss A, Thiele H, Ingendoh A. Even-electron ions: a systematic study of the neutral species lost in the dissociation of quasi-molecular ions. Journal of Mass Spectrometry 2007; 42: 1024.
45. McLafferty FW, Turecek F. Interpretation of Mass Spectra. University Science Books: Mill Valley, 1993.
46. Thevis M, Kohler M, Maurer J, Schlörer N, Kamber M, Schänzer W. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis. Rapid Communications in Mass Spectrometry 2007; 21: 3477.
47. Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biological and Pharmaceutical Bulletin 2003; 26: 1563.
48. Hanada K, Furuya K, Inoguchi K, Miyakawa M, Nagata K. Kaken Pharmaceutical. Tetrahydroquinoline Derivatives, EP 1 221 439 B1, 2007.
49. Thevis M, Kohler M, Schlörer N, Schänzer W. EI- and ESI-MS of selective androgen receptor modulators, 2008.
50. Murena F, Gioia F. Catalytic hydroprocessing of chlorobenzene-pyridine mixtures. Journal of Hazardous Materials 1998; 60: 271.
51. Eckert-Maksic M, Hodoscek M, Kovacek D, Maksic ZB, Primorac M. Theoretical model calculations of the absolute proton affinities of benzonitrile, nitroso- and nitrobenzene. Journal of Molecular Structure (Theochem) 1997; 417: 131.
52. Donike M, Zimmermann J. Zur Darstellung von Trimethylsilyl-, Triethylsilyl- und tert.- Butyldimethylsilyl- enoläthern von ketosteroiden für gas- chromatographische und massenspektrometrische Untersuchungen. Journal of Chromatography 1980; 202: 483.
53. Donike M, Zimmermann J, Bärwald KR, Schänzer W, Christ V, Klostermann K, Opfermann G. Routinebestimmung von anabolika in harn. Deutsche Zeitschrift fur Sportmedizin 1984; 35: 14.
54. Donike M. Acylierung mit Bis(Acylamiden); N-Methyl-Bis(Trifluoracetamid) und Bis(Trifluoracetamid), zwei neue reagenzien zur trifluoracefylierung. Journal of Chromatography 1973; 78: 273.
55. Hemmersbach P, de la Torre R. Stimulants, narcotics and β-blockers: 25 years of development in analytical techniques for doping control. Journal of Chromatography B 1996; 687: 221.
56. Locock RA, Courts RT. The mass spectra of succinimides, hydantoins, oxazolidinediones and other medicinal anti-epileptic agents. Organic Mass Spectrometry 1970; 3: 735.
57. Vouros P, Harvey DJ. Method for Selective Introduction of Trimethylsilyl and perdeuterotrimethylsilyl groups in hydroxy steroids and its utility in mass spectrometric interpretations. Analytical Chemistry 1973; 45: 7.
58. Dürbeck HW, Büker I. Studies on anabolic steroids. The mass spectra of 17α-Methyl-17β-hydroxy-1,4-androstadien-3-one (Dianabol) and its Metabolites. Biomedical Mass Spectrometry 1980; 7: 437.
59. Schänzer W, Horning S, Opfermann G, Donike M. Gas chromatography/mass spectometry identification of long-term excreted metabolites of the anabolic steroid 4-chloro-1,2-dehydro-17alpha-methyltestosterone in humans. Journal of Steroid Biochemistry and Molecular Biology 1996; 57: 363.
60. th Cologne Workshop on Doping Analysis, February 24-29, Cologne, 2008.
61. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatten CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Communications in Mass Spectometry 2004; 18: 1245.
62. Catlin DH, Ahrens BD, Kucherova Y. Detection of norbolethone, an anabolic steroid never marketed, in athletes' urine. Rapid Communications in Mass Spectometry 2002; 16: 1273.
63. Sekera MH, Ahrens BD, Chang YC, Starcevic B, Georgakopoulos C, Catlin DH. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid Communications in Mass Spectometry 2005; 19: 781.
64. Handelsman DJ. Designer androgens in sport: when too much is never enough. Science Signalling 2004; 244: pe41.
65. Thevis M, Kohler M, Thomas A, Maurer J, Schlörer N, Kamber M, Schänzer W. Determination of benzimidazole-and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. Analytical and Bioanalytical Chemistry 2008; 391: 251.